CLINICAL_TRIALS
withdrawal
· 2017-04-28
Clinical Trial Update: Evaluation of the Immune Restoration Potential Of Lenalidomide [Phase 2]
Summary
A Phase 2 trial evaluating lenalidomide for immune restoration in Chronic Lymphocytic Leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of California, San Diego | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: WITHDRAWN